Clinical trials
Chronic Hepatitis B clinical trials
Below are recruiting chronic hepatitis b clinical trials, each written for real people, not researchers. We’re tracking 170 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05869279RecruitingPhase 1/Phase 2
Study of donor immune cells for B-cell blood cancers
This Phase 1/2 study tests an “allogeneic” donor T-cell therapy (CARCIK-CD19) for children and adults with certain B-cell lymphomas and CLL who have tried multiple treatments. It may help by targeting cancer cells using engineered immune cells, but eligibility is complex and depends on donor availability and medical readiness.
Bergamo, BGAges 1 year+ - NCT04892277RecruitingPhase 1
CD19 CAR-T for adults with hard-to-treat B-cell cancers
This Phase 1 trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell cancers have come back or did not respond to treatment. It may help your immune system better recognize and attack cancer cells, but it is early research, so benefits and risks are still being defined.
Rochester, MinnesotaAges 18 years+ - NCT05832229RecruitingPhase 2
Liver cirrhosis network rosuvastatin trial
This study tests whether the drug rosuvastatin, a cholesterol-lowering medicine, can improve liver health in people with cirrhosis. If you have compensated cirrhosis (no recent serious liver problems), you might be able to join.
La Jolla, CaliforniaAges 18–75 - NCT05705570RecruitingPhase 1
CAR-T for CD19-positive relapsed or resistant blood cancers
This trial tests a type of immune treatment (CAR-T cells) for blood cancers that have come back or did not respond after standard treatments. It is for tumors that have CD19 on their cells, aiming to reduce the cancer and improve remission chances.
São Paulo, São PauloAges 2–70 - NCT07816094RecruitingPhase 4
Comparing two doses of entecavir for hepatitis B cirrhosis
This study tests two daily doses of the medicine entecavir to see which one better controls the hepatitis B virus in people with advanced liver scarring (cirrhosis). It aims to find the most effective dose to improve liver health.
Dhaka, Dhaka DivisionAges 18 years+ - NCT07668934Enrolling by invitationPhase 4
TAF for early and middle pregnancy with chronic hepatitis B
This trial tests a hepatitis B medicine called TAF in pregnant women who need antiviral treatment. It helps protect both mom and baby from complications of the virus.
Guangzhou, GuangdongAges 20–40 - NCT07589985Recruiting
Hepatitis B and Liver Health Study in Zambia
This research study follows people with hepatitis B (a liver infection) in Zambia to understand how their bodies respond to treatment and what happens to the virus over time. It includes people with hepatitis B alone, those also living with HIV, and those whose hepatitis B has cleared.
LusakaAges 18 years+ - NCT07542951Enrolling by invitationPhase 4
TAF vs TDF antiviral treatment during pregnancy for hepatitis B
This study compares two antiviral medications (TAF and TDF) in pregnant women with hepatitis B to see which is safer and more effective during pregnancy and for the baby's health.
Guangzhou, GuangdongAges 20–40 - NCT07454837RecruitingPhase 2/Phase 3
Switching to brelovitug for chronic hepatitis D patients on bulevirtide
This trial tests if switching from bulevirtide to brelovitug can help people with chronic hepatitis D (CHD). It is for adults who have been on bulevirtide for at least 6 months and still have detectable virus.
GrazAges 18 years+ - NCT07189377RecruitingPhase 4
Light, ex-vivo treatment and antivirals for lungs from hepatitis B donors
This trial tests a new way to safely use donor lungs that carry the hepatitis B virus (HBV). It combines a special light treatment, ex-vivo lung perfusion (cleaning the lungs outside the body), and antiviral medicines to prevent infection in the recipient. If you are on the lung transplant list and have been vaccinated against hepatitis B, this study may help expand your donor options.
Toronto, OntarioAges 18 years+ - NCT06947356Recruiting
TAF vs TDF to prevent passing hepatitis B to babies
This trial tests if TAF is safer and as effective as TDF for pregnant women with high hepatitis B viral loads to prevent passing the virus to their babies. You may qualify if you are pregnant, between 20-28 weeks, and have high viral levels.
Guangzhou, GuangdongAges 20–40 - NCT06966232RecruitingPhase 3
Using entecavir to prevent hepatitis B flare-up in gastrointestinal cancer patients
This trial tests whether giving the antiviral drug entecavir before or at the first sign of hepatitis B reactivation can prevent liver problems in gastrointestinal cancer patients who are inactive hepatitis B carriers and are starting chemotherapy or immunotherapy.
Guangzhou, GuangdongAges 18–75 - NCT06084234RecruitingPhase 4
National liver cancer screening trial
This trial is testing a new way to screen for liver cancer in people with cirrhosis or chronic hepatitis B. It aims to find cancer earlier so it can be treated more effectively.
Los Angeles, CaliforniaAges 18–85 - NCT04942886Enrolling by invitation
Preventing hepatitis B reactivation after stem cell transplant
This trial tests whether taking the antiviral medicine entecavir before and after a stem cell transplant can prevent hepatitis B from “waking up” again. It may help protect your liver during a high-risk treatment period.
SeoulAges 19–70 - NCT04357600Enrolling by invitationPhase 1/Phase 2
Stem cell treatment for hepatitis B–related cirrhosis
This early-stage trial tests umbilical cord “mesenchymal” stem cells in people with liver scarring (cirrhosis) that is caused by hepatitis B. It may help improve liver function and related complications, but it is mainly designed to check safety and how well the treatment works.
Jakarta, DKI JakartaAges 18–65 - NCT03773887Recruiting
Study of liver inflammation and healing in alcohol-related liver disease
This study compares patterns of liver inflammation and the liver’s healing ability in people with alcohol-related liver disease, using blood tests and (in most cases) a liver tissue sample. It may help doctors better understand what is happening in the liver and how it may recover.
LilleAges 18–70 - NCT05643742RecruitingPhase 1/Phase 2
Study of CTX112 for B-cell cancers that came back or did not respond
This Phase 1/2 study tests how safe and effective CTX112 is for adults whose B-cell cancer has returned or is not responding to treatment. It aims to see whether CTX112 can control the cancer while monitoring side effects closely.
Westwood, KansasAges 18 years+ - NCT06863402RecruitingPhase 2
Study of two drugs for Richter transformation lymphoma
This study tests a combination of two oral drugs (nemtabrutinib and pembrolizumab) for people with Richter transformation, an aggressive lymphoma that develops from chronic lymphocytic leukemia. It may be an option if standard chemotherapy is not suitable or if prior treatment has stopped working.
Buffalo, New YorkAges 18 years+ - NCT06859008RecruitingPhase 1
Zanubrutinib and sonrotoclax for B-cell lymphoma in diverse groups
This trial tests two targeted drugs, zanubrutinib and sonrotoclax, together for people with certain types of B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. It focuses on enrolling patients from racial and ethnic groups that are often underrepresented in research.
Duarte, CaliforniaAges 18 years+ - NCT04502394RecruitingPhase 1/Phase 2
Investigational drug combo for relapsed blood cancer
This trial combines two investigational drugs to see if they are safe and effective for patients with two types of blood cancer: diffuse large B-cell lymphoma (DLBCL) or chronic lymphocytic leukemia (CLL) that has come back or stopped responding to standard treatments. It may offer a new option when other treatments have not worked.
Goshen, IndianaAges 18 years+ - NCT05602363RecruitingPhase 1
Docirbrutinib for CLL or lymphoma after prior treatments
This Phase 1 study tests docirbrutinib, a targeted pill treatment, in people with CLL/SLL or certain other B-cell lymphomas that have come back or didn’t respond to earlier therapy. The goal is to see whether it’s safe and whether it can control the disease after standard treatments have failed.
Orange, CaliforniaAges 18 years+ - NCT04870437Recruiting
Light therapy study for kidney transplant rejection immune cells
This study looks at whether extra body light treatment (ECP) can change certain immune cells in people with a specific type of kidney transplant rejection caused by antibodies (cABMR). It’s meant to see if ECP could help manage the immune process after transplant.
BesançonAges 18 years+ - NCT06528301RecruitingPhase 1
Trial of UB-VV111 with or without rapamycin for B-cell cancers
This trial tests a new therapy called UB-VV111, alone or with rapamycin, in people with certain types of lymphoma or leukemia that have come back or not responded to treatment. The goal is to see if it's safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT03595917RecruitingPhase 1
New and hard-to-treat BCR-ABL leukemia drugs plus prednisone and blinatumomab
This Phase 1 study tests a combination of targeted cancer drugs with prednisone and blinatumomab in people with BCR-ABL–positive B-cell leukemia (B-ALL), or chronic myeloid leukemia (CML) in lymphoid blast crisis. It may help by attacking leukemia cells through multiple pathways, especially when standard intensive chemotherapy is not suitable.
Chicago, IllinoisAges 18 years+
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic hepatitis b?
- Yes. Clin2 currently lists 170 recruiting chronic hepatitis b studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic hepatitis b trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic hepatitis b trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.